Mobilized CD34+ Stem Cells
This white paper gives background on the history of CD34+ stem cell mobilization and provides a comprehensive analysis examining how different mobilization agents, dosing schedules, and blood volume processed can impact CD34+ stem cell yields in mobilized leukopaks.
Hematopoietic stem and progenitor cell mobilization is the recruitment of CD34+ stem cells out of the bone marrow and into the peripheral blood circulation. Collection of mobilized peripheral blood by apheresis (leukapheresis) is a relatively low risk procedure for the donor and is usually well tolerated. While the percentage of CD34+ stem cells in the mobilized leukapheresis product (mobilized leukopak) varies due to donor and dosing regimen differences, they are comparable to those derived from other CD34+ stem cell sources.
Currently, mobilized peripheral blood is the predominant source of CD34+ stem cells for research support and clinical use. Other sources of CD34+ stem cells include bone marrow aspirate and umbilical cord blood. The preference for mobilized peripheral blood is primarily due to accessibility, relative ease of sourcing, and increased recallability potential for the donors. In addition, collection volumes of mobilized leukopaks are significantly greater than for either cord blood or bone marrow collections, normally leading to higher overall yields of CD34+ stem cells.